title: Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.
abstract: OBJECTIVE
  To investigate highly active antiretroviral therapy (HAART) initiation among pregnant women and the optimum model of service delivery for integrating HAART services into antenatal care.
  
  
  METHODS
  We analysed clinic records to reconstruct a cohort of all HIV-infected pregnant women eligible for HAART at four antenatal clinics representing three service delivery models in Cape Town, South Africa. To assess HAART coverage, records of women determined to be eligible for HAART in pregnancy were reviewed at corresponding HIV treatment services.
  
  
  RESULTS
  Of 13,208 pregnant women tested for HIV, 26% were HIV-infected and 15% were HAART-eligible based on a CD4 cell count of <or= 200 cells/microl. Among eligible women, 51% initiated HAART before delivery, 27% received another prevention of mother-to-child transmission (PMTCT) intervention and 22% did not receive any antiretroviral intervention before delivery. The proportions of women initiating HAART between the different service delivery models were comparable. The median gestational age at first presentation was 26 weeks, and early gestational age at first presentation was the strongest predictor of being on HAART by delivery. Of the women who did not initiate HAART in pregnancy, 24% started treatment within 2 years postpartum.
  
  
  CONCLUSIONS
  In this setting with clear PMTCT and HAART protocols, services failed to prioritize and initiate a high proportion of eligible pregnant women on HAART. The initiation of HAART in pregnancy requires strengthened antenatal and HIV services that target women with advanced stage disease.
authors.affiliation: Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Stinson
authors.forename: Andrew
authors.initials: A
authors.lastname: Boulle
authors.forename: David
authors.initials: D
authors.lastname: Coetzee
authors.forename: Elaine J
authors.initials: EJ
authors.lastname: Abrams
authors.forename: Landon
authors.initials: L
authors.lastname: Myer
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data*; D018791:CD4 Lymphocyte Count; D019033:Delivery of Health Care, Integrated / Q000458:organization & administration; D005260:Female; D005865:Gestational Age; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D017146:Models, Organizational; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011295:Prenatal Care / Q000458:organization & administration; D012189:Retrospective Studies; D013019:South Africa; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents